

**Supplemental Table 1. Medication use during the 3-year follow-up period**

	CABG (n=956)			PCI (n=948)			CABG vs. PCI	
	No diabetes (n=688)	Diabetes (n=268)	p- Value	No diabetes (n=662)	Diabetes (n=286)	p- Value	p-Value No Diabetes	p-Value Diabetes
Aspirin								
Discharge	98.9 (651/658)	98.8 (245/248)	0.90	98.9 (641/648)	99.3 (278/280)	0.57	>0.99	0.55
6 months	97.7 (644/659)	96.8 (243/251)	0.44	97.7 (631/646)	97.8 (268/274)	0.93	>0.99	0.48
12 months	96.3 (629/653)	96.4 (239/248)	0.94	95.8 (614/641)	98.9 (264/267)	0.02	0.65	0.06
24 months	95.3 (591/620)	96.2 (229/238)	0.57	94.4 (586/621)	99.2 (243/245)	0.002	0.47	0.03
36 months	95.5 (569/596)	95.3 (224/235)	0.90	92.7 (559/603)	98.7 (230/233)	<0.001	0.039	0.03
P2Y12 inhibitor								
Discharge	33.7 (223/661)	30.4 (76/250)	0.34	98.3 (639/650)	97.2 (273/281)	0.28	<0.001	<0.001
6 months	27.8 (184/662)	28.3 (72/254)	0.88	97.4 (631/648)	97.1 (267/275)	0.79	<0.001	<0.001
12 months	25.2 (165/656)	26.0 (65/250)	0.80	83.8 (539/643)	84.3 (226/268)	0.85	<0.001	<0.001
24 months	21.8 (136/623)	24.6 (59/240)	0.38	69.2 (431/623)	72.0 (177/246)	0.42	<0.001	<0.001
36 months	21.0 (126/599)	24.9 (59/237)	0.22	65.8 (398/605)	69.2 (162/234)	0.35	<0.001	<0.001
DAPT								
Discharge	33.4 (221/661)	28.8 (72/250)	0.18	97.4 (633/650)	96.1 (270/281)	0.28	<0.001	<0.001
6 months	26.7 (177/662)	27.2 (69/254)	0.88	95.4 (618/648)	94.5 (260/275)	0.56	<0.001	<0.001
12 months	23.5 (154/656)	25.2 (63/250)	0.59	80.6 (518/643)	82.8 (222/268)	0.44	<0.001	<0.001
24 months	19.6 (122/623)	23.3 (56/240)	0.23	64.5 (402/623)	70.7 (174/246)	0.08	<0.001	<0.001
36 months	18.7 (112/599)	23.6 (56/237)	0.11	60.5 (366/605)	67.5 (158/234)	0.06	<0.001	<0.001
Statin								
Discharge	92.6 (612/661)	92.0 (230/250)	0.76	96.0 (624/650)	97.5 (274/281)	0.25	0.008	0.04
6 months	95.0 (626/659)	93.7 (237/253)	0.44	96.6 (624/646)	97.5 (268/275)	0.47	0.15	0.03
12 months	96.3 (626/650)	94.0 (233/248)	0.13	96.7 (621/642)	97.4 (261/268)	0.58	0.70	0.055
24 months	96.8 (602/622)	93.7 (24/239)	0.04	96.9 (603/622)	97.2 (239/246)	0.82	0.92	0.06
36 months	97.0 (580/598)	93.2 (220/236)	0.01	96.7 (585/605)	97.4 (228/234)	0.60	0.76	0.03
Beta-blocker								
Discharge	92.7 (613/661)	92.0 (230/250)	0.72	83.1 (540/650)	83.6 (235/281)	0.85	<0.001	0.003
6 months	94.4 (624/661)	92.9 (234/252)	0.39	84.5 (546/646)	86.1 (236/274)	0.54	<0.001	0.01
12 months	94.5 (620/656)	93.5 (232/248)	0.56	85.2 (546/641)	86.5 (231/267)	0.61	<0.001	0.008
24 months	95.3 (593/622)	93.3 (223/239)	0.24	85.0 (528/621)	86.2 (212/246)	0.65	<0.001	0.01
36 months	94.5 (566/599)	92.8 (219/236)	0.35	85.6 (516/603)	87.6 (205/234)	0.45	<0.001	0.06

ACEI or ARB								
Discharge	40.7 (269/661)	46.0 (115/250)	0.15	57.5 (374/650)	54.8 (154/281)	0.45	<0.001	0.04
6 months	47.9 (311/649)	56.2 (141/251)	0.03	61.3 (396/646)	58.8 (160/272)	0.48	<0.001	0.55
12 months	52.0 (333/641)	60.8 (149/245)	0.02	62.7 (400/638)	61.9 (164/265)	0.82	<0.001	0.80
24 months	53.9 (332/616)	61.3 (146/238)	0.051	64.7 (400/618)	63.9 (156/244)	0.83	<0.001	0.55
36 months	54.6 (325/595)	64.4 (150/233)	0.01	64.4 (389/604)	65.8 (152/231)	0.70	<0.001	0.75

---

Values are presented as % (n/N). ACEI = angiotensin-converting enzyme inhibitors; ARB = angiotensin II receptor blockers; CABG = coronary artery bypass grafting; DAPT = dual antiplatelet therapy; PCI = percutaneous coronary intervention.

**Supplemental Table 2. Incidence and 30-day outcomes of acute renal failure**

	All (n=1904)			No Diabetes (n=1350)			Diabetes (n=554)			Pinteraction
	No diabetes (n = 1350)	Diabetes (n = 554)	p Value	CABG (n = 688)	PCI (n = 662)	p Value	CABG (n = 268)	PCI (n = 286)	p Value	
Acute renal failure	1.1 (15)	2.7 (15)	0.01	1.9 (13)	0.3 (2)	0.005	4.1 (11)	1.4 (4)	0.050	0.44
New requirement for dialysis	0.6 (8)	1.6% (9)	0.03	0.9 (6)	0.3 (2)	0.29	3.0 (8)	0.4 (1)	0.02	0.41
Hemodialysis	0.4 (5)	0.9 (5)	0.17	0.6 (4)	0.2 (1)	0.37	1.5 (4)	0.4 (1)	0.20	0.94
CVVH	0.3 (3)	0.7 (4)	0.24	0.3 (2)	0.3 (2)	1.00	1.5 (4)	0.0 (0)	0.054	0.95
Outcomes in ARF patients										
Death, stroke, or MI	20.0 (3)	33.0 (5)	0.47	15.4 (2)	50.0 (1)	0.15	45.5 (5)	0.0 (0)	0.13	1.00
Death, stroke, MI, or IDR	20.0 (3)	33.3 (5)	0.46	15.4 (2)	50.0 (1)	0.15	45.5 (5)	0.0 (0)	0.13	1.00
Death	6.7 (1)	6.7 (1)	0.98	7.7 (1)	0.0 (0)	0.69	9.1 (1)	0.0 (0)	0.55	1.00
Stroke	0.0 (0)	13.9 (2)	0.16	0.0 (0)	0.0 (0)	—	19.2 (2)	0.0 (0)	0.37	1.00
MI	20.0 (3)	13.3 (2)	0.62	15.4 (2)	50.0 (1)	0.15	18.2 (2)	0.0 (0)	0.38	1.00
All repeat revascularizations	7.1 (1)	13.3 (2)	0.56	8.3 (1)	0.0 (0)	0.68	18.2 (2)	0.0 (0)	0.38	1.00
IDR	7.1 (1)	13.3 (2)	0.56	8.3 (1)	0.0 (0)	0.68	18.2 (2)	0.0 (0)	0.38	1.00
PCI	7.1 (1)	13.3 (2)	0.56	8.3 (1)	0.0 (0)	0.68	18.2 (2)	0.0 (0)	0.38	1.00
CABG	0.0 (0)	0.0 (0)	—	0.0 (0)	0.0 (0)	—	0.0 (0)	0.0 (0)	—	—
Graft occlusion or stent thrombosis	7.1 (1)	6.7 (1)	1.00	8.3 (1)	0.0 (0)	0.68	9.1 (1)	0.0 (0)	0.55	1.00

Values are Kaplan-Meier time-to-first event estimates expressed as % (n). ARF = acute renal failure; CABG = coronary artery bypass grafting; CVVH = continuous veno-venous hemofiltration; IDR = ischemia-driven revascularization; MI = myocardial infarction; PCI = percutaneous coronary intervention.

**Supplemental Table 3. Three-year clinical outcomes in diabetic patients according to insulin treatment and revascularization assignment**

	All Diabetes (n = 554)			No Insulin (n = 407)			Insulin (n = 147)			Pinteraction
	No insulin (n = 407)	Insulin (n = 147)	p Value	CABG (n = 194)	PCI (n = 213)	p Value	CABG (n = 74)	PCI (n = 73)	p Value	
Death, stroke, or MI	18.4 (74)	24.5 (35)	0.10	18.3 (35)	18.5 (39)	0.92	22.2 (16)	26.9 (19)	0.61	0.63
Death, stroke, MI, or IDR	23.7 (95)	32.8 (47)	0.03	20.9 (40)	26.2 (55)	0.31	27.8 (20)	38.2 (27)	0.29	0.77
Death	11.0 (44)	10.6 (15)	0.92	7.8 (15)	13.8 (29)	0.07	8.4 (6)	13.0 (9)	0.42	0.82
Cardiovascular	5.6 (22)	7.9 (11)	0.34	5.3 (10)	5.9 (12)	0.82	5.7 (4)	10.2 (7)	0.35	0.52
Stroke	3.4 (13)	4.4 (6)	0.59	4.8 (9)	2.0 (4)	0.12	5.7 (4)	3.2 (2)	0.43	0.83
MI	8.6 (34)	15.8 (22)	0.02	9.1 (17)	8.3 (17)	0.73	15.4 (11)	16.4 (11)	0.95	0.81
Periprocedural	4.0 (16)	6.9 (10)	0.15	5.2 (10)	2.8 (6)	0.23	8.3 (6)	5.5 (4)	0.56	0.77
Spontaneous	4.7 (18)	11.1 (15)	0.009	3.9 (7)	5.5 (11)	0.46	10.1 (7)	12.3 (8)	0.78	0.77
All repeat revascularizations	11.2 (43)	18.5 (25)	0.03	7.6 (14)	14.4 (29)	0.04	13.1 (9)	24.3 (16)	0.14	0.92
IDR	10.9 (42)	18.5 (25)	0.02	7.1 (13)	14.4 (29)	0.02	13.1 (9)	24.3 (16)	0.14	0.81
PCI	9.9 (38)	14.8 (20)	0.11	7.1 (13)	12.3 (25)	0.09	11.6 (8)	18.3 (12)	0.37	0.77
CABG	1.6 (6)	3.8 (5)	0.13	0	3.1 (6)	0.02	1.5 (1)	6.1 (4)	0.17	0.99
Graft occlusion or stent thrombosis	2.8 (11)	7.3 (10)	0.02	4.9 (9)	1.0 (2)	0.02	11.7 (8)	2.9 (2)	0.053	0.85

Values are Kaplan-Meier time-to-first event estimates expressed as % (n). CABG = coronary artery bypass grafting; IDR = ischemia-driven revascularization; MI = myocardial infarction; PCI = percutaneous coronary intervention.

**Supplemental Table 4. Three-Year Clinical Outcomes According to Diabetes Status, Site-Reported SYNTAX Score, and Revascularization**

	<i>SYNTAX Score 0-22</i>			<i>SYNTAX Score 23-32</i>		
	<b>CABG</b>	<b>PCI</b>	<b>p Value</b>	<b>CABG</b>	<b>PCI</b>	<b>p Value</b>
Diabetic cohort	(n=160)	(n=156)		(n=108)	(n=129)	
Death, stroke, or MI	17.0 (27)	17.0 (26)	0.88	22.8 (24)	25.0 (32)	0.84
Death, stroke, MI, or IDR	20.2 (32)	26.2 (40)	0.30	26.6 (28)	32.8 (42)	0.45
Death	7.0 (11)	8.6 (13)	0.64	9.6 (10)	19.6 (25)	0.04
Cardiovascular	4.5 (7)	2.7 (4)	0.39	6.8 (7)	12.1 (15)	0.19
Stroke	5.8 (9)	2.1 (3)	0.09	2.5 (3)	4.0 (4)	0.54
MI	7.7 (12)	9.5 (14)	0.66	15.5 (16)	11.1 (14)	0.34
Periprocedural	3.1 (5)	1.3 (2)	0.27	10.5 (11)	6.2 (8)	0.26
Spontaneous	5.3 (8)	8.2 (12)	0.34	6.1 (6)	5.8 (7)	0.92
All repeat revascularization	8.5 (13)	17.0 (25)	0.04	10.1 (10)	16.5 (20)	0.17
IDR	7.8 (12)	17.0 (25)	0.02	10.1 (10)	16.5 (20)	0.17
PC	7.1 (11)	12.9 (19)	0.12	10.1 (10)	14.8 (18)	0.29
CABG	0.7 (1)	4.1 (6)	0.053	0	3.4 (4)	0.07
Graft occlusion or stent thrombosis	7.2 (11)	2.0 (3)	0.03	5.9 (6)	0.8 (1)	0.03
Non-diabetic cohort	(n=430)	(n=403)		(n=257)	(n=258)	
Death, stroke, or MI	13.2 (55)	13.1 (52)	0.90	12.5 (31)	12.5 (32)	0.96
Death, stroke, MI, or IDR	17.9 (74)	18.7 (74)	0.85	16.9 (42)	22.7 (58)	0.14
Death	5.6 (23)	5.3 (21)	0.84	4.1 (10)	5.9 (15)	0.36
Cardiovascular	3.7 (15)	3.1 (12)	0.62	2.1 (5)	3.5 (9)	0.31
Stroke	2.3 (9)	2.3 (9)	0.95	2.4 (6)	2.4 (6)	0.96
MI	7.7 (32)	7.1 (28)	0.72	7.2 (18)	7.1 (18)	0.93
Periprocedural	6.4 (27)	4.0 (16)	0.13	5.5 (14)	3.9 (10)	0.40
Spontaneous	1.5 (6)	3.1 (12)	0.14	1.6 (4)	3.2 (8)	0.27
All repeat revascularization	7.5 (30)	9.3 (36)	0.37	6.2 (15)	14.4 (36)	0.003
IDR	7.5 (30)	9.1 (35)	0.44	6.2 (15)	14.0 (35)	0.005
PCI	6.6 (26)	7.8 (30)	0.50	5.4 (13)	11.2 (28)	0.02

CABG	0.9 (4)	2.9 (11)	0.06	0.8 (2)	3.6 (9)	0.04
Graft occlusion or stent thrombosis	4.7 (19)	0.5 (2)	<0.001	5.0 (12)	0.4 (1)	0.002

Values are Kaplan-Meier time-to-event estimates expressed as % (n). CABG = coronary artery bypass grafting; IDR = ischemia-driven revascularization; MI = myocardial infarction; PCI = percutaneous coronary intervention.

**Supplemental Table 5. Three-Year Clinical Outcomes According to Diabetes Status, Core Lab SYNTAX Score, and Revascularization**

	<i>SYNTAX score 0-22</i>			<i>SYNTAX Score 23-32</i>			<i>SYNTAX score ≥33</i>		
	<b>CABG</b>	<b>PCI</b>	<b>P Value</b>	<b>CABG</b>	<b>PCI</b>	<b>P Value</b>	<b>CABG</b>	<b>PCI</b>	<b>p Value</b>
Diabetic cohort	(n=94)	(n=73)		(n=99)	(n=135)		(n=70)	(n=66)	
Death, stroke, or MI	16.2 (15)	14.1 (10)	0.69	24.7 (24)	23.0 (31)	0.61	14.5 (10)	20.2 (13)	0.48
Death, stroke, MI or IDR	21.6 (20)	19.8 (14)	0.72	26.8 (26)	33.4 (45)	0.46	17.4 (12)	27.9 (18)	0.20
Death	8.7 (8)	5.7 (4)	0.44	9.3 (9)	16.4 (22)	0.14	5.8 (4)	15.8 (10)	0.07
Cardiovascular	6.6 (6)	1.5 (1)	0.11	4.2 (4)	8.3 (11)	0.22	5.8 (4)	10.0 (6)	0.41
Stroke	6.6 (6)	1.4 (1)	0.10	4.3 (4)	2.4 (3)	0.43	4.4 (3)	3.4 (2)	0.71
MI	5.6 (5)	9.9 (7)	0.29	13.6 (13)	10.1 (13)	0.33	11.6 (8)	7.9 (5)	0.45
Periprocedural	2.2 (2)	4.1 (3)	0.45	7.2 (7)	3.0 (4)	0.14	8.7 (6)	3.0 (2)	0.17
Spontaneous	3.5 (3)	5.9 (4)	0.48	7.5 (7)	7.2 (9)	0.83	4.5 (3)	6.5 (4)	0.61
All repeat revascularization	7.9 (7)	11.7 (8)	0.48	10.8 (10)	21.3 (27)	0.06	7.5 (5)	12.8 (8)	0.31
IDR	7.9 (7)	11.7 (8)	0.48	10.8 (10)	21.3 (27)	0.06	6.1 (4)	12.8 (8)	0.17
PCI	6.7 (6)	8.8 (6)	0.70	10.8 (10)	18.1 (23)	0.18	6.1 (4)	11.2 (7)	0.27
CABG	1.2 (1)	2.9 (2)	0.44	0	4.8 (6)	0.04	0	1.6 (1)	0.30
Graft occlusion or stent thrombosis	5.7 (5)	1.5 (1)	0.16	7.6 (7)	1.6 (2)	0.03	7.4 (5)	0	0.03
Nondiabetic cohort	(n=270)	(n=221)		(n=246)	(n=256)		(n=146)	(n=163)	
Death, stroke, or MI	12.3 (32)	9.2 (20)	0.21	13.4 (32)	14.7 (37)	0.69	14.0 (20)	14.8 (24)	0.89
Death, stroke, MI, or IDR	18.6 (48)	15.1 (33)	0.23	18.9 (45)	22.7 (57)	0.32	14.0 (20)	24.0 (39)	0.04
Death	4.7 (12)	3.7 (8)	0.55	5.1 (12)	6.8 (17)	0.44	5.7 (8)	6.2 (10)	0.84
Cardiovascular	2.4 (6)	1.8 (4)	0.69	3.4 (8)	4.0 (10)	0.73	3.6 (5)	4.4 (7)	0.72
Stroke	2.0 (5)	1.4 (3)	0.61	2.6 (6)	2.4 (6)	0.91	1.4 (2)	3.8 (6)	0.21
MI	6.9 (18)	5.1 (11)	0.35	7.5 (18)	8.4 (21)	0.72	9.2 (13)	7.5 (12)	0.58
Periprocedural	5.6 (15)	0.9 (2)	0.005	5.8 (14)	5.9 (15)	0.91	7.7 (11)	4.3 (7)	0.22
Spontaneous	1.2 (3)	4.2 (9)	0.05	1.7 (4)	2.5 (6)	0.59	2.2 (3)	3.2 (5)	0.59
All repeat revascularization	7.6 (19)	9.7 (21)	0.45	8.7 (20)	11.8 (29)	0.25	2.9 (4)	14.1 (22)	<0.001
IDR	7.6 (19)	9.3 (20)	0.56	8.7 (20)	11.4 (28)	0.31	2.9 (4)	14.1 (22)	<0.001

PCI	7.2 (18)	6.5 (14)	0.74	7.1 (16)	10.2 (25)	0.19	2.2 (3)	12.2 (19)	0.001
CABG	0.4 (1)	3.7 (8)	0.01	1.7 (4)	2.9 (7)	0.42	0.7 (1)	3.2 (5)	0.14
Graft occlusion or stent thrombosis	4.4 (11)	0.9 (2)	0.02	5.6 (13)	0.4 (1)	<0.001	2.9 (4)	0	0.03

Values are Kaplan-Meier time-to-event estimates expressed as % (n); log-rank p-value. CABG = coronary artery bypass grafting; IDR = ischemia-driven revascularization; MI = myocardial infarction; PCI = percutaneous coronary intervention.

**Supplemental Table 6. Independent Predictors of Adverse Events in the CABG Cohort**

	<b>Hazard Ratio (95% Confidence Interval)</b>	<b>p Value</b>
Death, stroke, or MI		
Diabetes versus non-diabetes	1.55 (1.04-2.31)	0.03
Hypertension treated with medication	1.67 (1.02-2.72)	0.04
Death, stroke, MI, or IDR		
Hyperlipidemia treated with medication	0.66 (0.46-0.94)	0.02
All-cause death		
Current smoker	2.30 (1.11-4.79)	0.03
Left ventricular ejection fraction (%)	0.96 (0.94-0.99)	0.01
MI		
Age	0.96 (0.94-0.99)	0.009
Recent MI	1.84 (1.01-3.37)	0.048
Hypertension treated with medication	2.19 (1.14-4.18)	0.02
Hyperlipidemia treated with medication	0.56 (0.33-0.93)	0.03
Stroke		
Diabetes versus non-diabetes	3.38 (1.39-8.24)	0.007
IDR		
Age	0.96 (0.93-0.99)	0.01
Male	0.55 (0.30-0.99)	0.046
Hyperlipidemia treated with medication	0.30 (0.17-0.52)	<0.001

CABG = coronary artery bypass grafting; IDR = ischemia-driven revascularization; MI = myocardial infarction.

**Supplemental Table 7. Independent predictors of adverse events in the PCI cohort**

	<b>Hazard Ratio (95% Confidence Interval)</b>	<b>p Value</b>
Death, stroke, or MI		
Diabetes versus non-diabetes	1.53 (1.04-2.26)	0.03
Age	1.03 (1.01-1.06)	0.008
Death, stroke, MI, or IDR		
Age	1.02 (1.00-1.04)	0.03
SYNTAX score	1.02 (1.00-1.03)	0.048
All-cause death		
Diabetes versus non-diabetes	2.51 (1.46-4.31)	<0.001
Age	1.06 (1.03-1.10)	<0.001
MI		
Body mass index	1.06 (1.01-1.11)	0.02
Stroke		
Male sex	0.34 (0.12-0.91)	0.03
Body mass index	0.87 (0.76-1.00)	0.04
IDR		
None identified	—	—

IDR = ischemia-driven revascularization; MI, myocardial infarction; PCI = percutaneous coronary intervention.

## **Supplemental Figure 1. Three-Year Outcomes for Diabetic and Nondiabetic Patients**

### **According to Anatomic Lesion Complexity as Measured by the Core Laboratory-Assessed SYNTAX Score**

Kaplan-Meier estimates of the composite endpoint of all-cause death, stroke, or myocardial infarction (MI); the composite endpoint of all-cause death, stroke, MI, or ischemia-driven repeat revascularization (IDR); all-cause death; and IDR in diabetic patients (A-D) and non-diabetic patients (E-H). Treatment by SYNTAX score interactions in the diabetic and the non-diabetic groups: The composite endpoint of all-cause death, stroke, or MI ( $p_{\text{int}}=0.64$  and  $p_{\text{int}}=0.47$ ); the composite endpoint of all-cause death, stroke, MI, or IDR ( $p_{\text{int}}=0.48$  and  $p_{\text{int}}=0.056$ ); all-cause death ( $p_{\text{int}}=0.20$  and  $p_{\text{int}}=0.64$ ); and IDR ( $p_{\text{int}}=0.82$  and  $p_{\text{int}}=0.058$ ). P values are from log-rank test. Rates are separated according to the site-reported SYNTAX score values, indicating low (0–22), intermediate (23–32), and high ( $\geq 33$ ) anatomic lesion complexity. CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention.

# Supplemental Figure 1

